NCT04487080 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 429
- group Id
- BG001
- value
- 429
- group Id
- BG002
- value
- 216
- group Id
- BG003
- value
- 1074
- units
- Participants
- groups
- description
- Participants received combination therapy of amivantamab 1050 milligrams (mg) for body weight (BW) less than (\<) 80 kilograms (kg) or 1400 mg for BW greater than or equal to (\>=) 80 kg intravenous (IV) infusion once weekly in 28-day treatment cycles: at Cycle 1 Days 1/2 (split dose, Day 1: 350 mg regardless of BW; Day 2: 700 mg or 1050 mg \[if BW \>=80 kg\]), 8, 15, and 22 and then once every 2 weeks (at Day 1 and 15) from Cycle 2 onwards; and lazertinib 240 mg (3 tablets of 80 mg) orally once daily. Participants continued treatment until disease progression, participant consent withdrawal, adverse event, investigator's decision, or initiation of new systemic anti-cancer treatment.
- id
- BG000
- title
- Experimental: Arm A (Open-label): Amivantamab + Lazertinib
- description
- Participants received osimertinib 80 mg capsule orally once daily along with 3 tablets of matching placebo of lazertinib 240 mg tablets orally once daily from Cycle 1 Day 1 until disease progression, participant consent withdrawal, adverse event, investigator's decision, or initiation of new systemic anti-cancer treatment.
- id
- BG001
- title
- Active Comparator: Arm B (Double-blind): Osimertinib+Placebo Matching Lazertinib
- description
- Participants received lazertinib 240 mg (3 tablets of 80 mg) orally once daily along with single capsule of matching placebo of osimertinib 80 mg orally once daily from Cycle 1 Day 1 until disease progression, participant consent withdrawal, adverse event, investigator's decision, or initiation of new systemic anti-cancer treatment.
- id
- BG002
- title
- Experimental: Arm C (Double-blind): Lazertinib+Placebo Matching Osimertinib
- description
- Total of all reporting groups
- id
- BG003
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 10.63
- value
- 62.7
- group Id
- BG001
- spread
- 11.52
- value
- 61.9
- group Id
- BG002
- spread
- 10.69
- value
- 61.3
- group Id
- BG003
- spread
- 11.01
- value
- 62.1
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 275
- group Id
- BG001
- value
- 251
- group Id
- BG002
- value
- 136
- group Id
- BG003
- value
- 662
- title
- Female
- measurements
- group Id
- BG000
- value
- 154
- group Id
- BG001
- value
- 178
- group Id
- BG002
- value
- 80
- group Id
- BG003
- value
- 412
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 56
- group Id
- BG001
- value
- 45
- group Id
- BG002
- value
- 24
- group Id
- BG003
- value
- 125
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 371
- group Id
- BG001
- value
- 382
- group Id
- BG002
- value
- 190
- group Id
- BG003
- value
- 943
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 6
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 7
- group Id
- BG001
- value
- 7
- group Id
- BG002
- value
- 4
- group Id
- BG003
- value
- 18
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 250
- group Id
- BG001
- value
- 251
- group Id
- BG002
- value
- 128
- group Id
- BG003
- value
- 629
- title
- Asian
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 2
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 4
- group Id
- BG003
- value
- 11
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 164
- group Id
- BG001
- value
- 165
- group Id
- BG002
- value
- 79
- group Id
- BG003
- value
- 408
- title
- White
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 2
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 4
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 8
- group Id
- BG001
- value
- 11
- group Id
- BG002
- value
- 6
- group Id
- BG003
- value
- 25
- title
- ARGENTINA
- categories
- measurements
- group Id
- BG000
- value
- 5
- group Id
- BG001
- value
- 7
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 13
- title
- AUSTRALIA
- categories
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 7
- title
- BELGIUM
- categories
- measurements
- group Id
- BG000
- value
- 38
- group Id
- BG001
- value
- 22
- group Id
- BG002
- value
- 9
- group Id
- BG003
- value
- 69
- title
- BRAZIL
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 2
- title
- CANADA
- categories
- measurements
- group Id
- BG000
- value
- 81
- group Id
- BG001
- value
- 79
- group Id
- BG002
- value
- 43
- group Id
- BG003
- value
- 203
- title
- CHINA
- categories
- measurements
- group Id
- BG000
- value
- 12
- group Id
- BG001
- value
- 11
- group Id
- BG002
- value
- 6
- group Id
- BG003
- value
- 29
- title
- FRANCE
- categories
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 9
- title
- GERMANY
- categories
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 3
- title
- HUNGARY
- categories
- measurements
- group Id
- BG000
- value
- 6
- group Id
- BG001
- value
- 16
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 25
- title
- INDIA
- categories
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 8
- title
- ISRAEL
- categories
- measurements
- group Id
- BG000
- value
- 11
- group Id
- BG001
- value
- 8
- group Id
- BG002
- value
- 5
- group Id
- BG003
- value
- 24
- title
- ITALY
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Region of Enrollment
- unit Of Measure
- Participants
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 429
- group Id
- BG001
- value
- 429
- group Id
- BG002
- value
- 216
- group Id
- BG003
- value
- 1074
- units
- Participants
- groups
- description
- Participants received combination therapy of amivantamab 1050 milligrams (mg) for body weight (BW) less than (\<) 80 kilograms (kg) or 1400 mg for BW greater than or equal to (\>=) 80 kg intravenous (IV) infusion once weekly in 28-day treatment cycles: at Cycle 1 Days 1/2 (split dose, Day 1: 350 mg regardless of BW; Day 2: 700 mg or 1050 mg \[if BW \>=80 kg\]), 8, 15, and 22 and then once every 2 weeks (at Day 1 and 15) from Cycle 2 onwards; and lazertinib 240 mg (3 tablets of 80 mg) orally once daily. Participants continued treatment until disease progression, participant consent withdrawal, adverse event, investigator's decision, or initiation of new systemic anti-cancer treatment.
- id
- BG000
- title
- Experimental: Arm A (Open-label): Amivantamab + Lazertinib
- description
- Participants received osimertinib 80 mg capsule orally once daily along with 3 tablets of matching placebo of lazertinib 240 mg tablets orally once daily from Cycle 1 Day 1 until disease progression, participant consent withdrawal, adverse event, investigator's decision, or initiation of new systemic anti-cancer treatment.
- id
- BG001
- title
- Active Comparator: Arm B (Double-blind): Osimertinib+Placebo Matching Lazertinib
- description
- Participants received lazertinib 240 mg (3 tablets of 80 mg) orally once daily along with single capsule of matching placebo of osimertinib 80 mg orally once daily from Cycle 1 Day 1 until disease progression, participant consent withdrawal, adverse event, investigator's decision, or initiation of new systemic anti-cancer treatment.
- id
- BG002
- title
- Experimental: Arm C (Double-blind): Lazertinib+Placebo Matching Osimertinib
- description
- Total of all reporting groups
- id
- BG003
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 10.63
- value
- 62.7
- group Id
- BG001
- spread
- 11.52
- value
- 61.9
- group Id
- BG002
- spread
- 10.69
- value
- 61.3
- group Id
- BG003
- spread
- 11.01
- value
- 62.1
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 275
- group Id
- BG001
- value
- 251
- group Id
- BG002
- value
- 136
- group Id
- BG003
- value
- 662
- title
- Female
- measurements
- group Id
- BG000
- value
- 154
- group Id
- BG001
- value
- 178
- group Id
- BG002
- value
- 80
- group Id
- BG003
- value
- 412
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 56
- group Id
- BG001
- value
- 45
- group Id
- BG002
- value
- 24
- group Id
- BG003
- value
- 125
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 371
- group Id
- BG001
- value
- 382
- group Id
- BG002
- value
- 190
- group Id
- BG003
- value
- 943
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 6
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 7
- group Id
- BG001
- value
- 7
- group Id
- BG002
- value
- 4
- group Id
- BG003
- value
- 18
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 250
- group Id
- BG001
- value
- 251
- group Id
- BG002
- value
- 128
- group Id
- BG003
- value
- 629
- title
- Asian
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 2
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 4
- group Id
- BG003
- value
- 11
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 164
- group Id
- BG001
- value
- 165
- group Id
- BG002
- value
- 79
- group Id
- BG003
- value
- 408
- title
- White
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 2
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 4
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 8
- group Id
- BG001
- value
- 11
- group Id
- BG002
- value
- 6
- group Id
- BG003
- value
- 25
- title
- ARGENTINA
- categories
- measurements
- group Id
- BG000
- value
- 5
- group Id
- BG001
- value
- 7
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 13
- title
- AUSTRALIA
- categories
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 7
- title
- BELGIUM
- categories
- measurements
- group Id
- BG000
- value
- 38
- group Id
- BG001
- value
- 22
- group Id
- BG002
- value
- 9
- group Id
- BG003
- value
- 69
- title
- BRAZIL
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 2
- title
- CANADA
- categories
- measurements
- group Id
- BG000
- value
- 81
- group Id
- BG001
- value
- 79
- group Id
- BG002
- value
- 43
- group Id
- BG003
- value
- 203
- title
- CHINA
- categories
- measurements
- group Id
- BG000
- value
- 12
- group Id
- BG001
- value
- 11
- group Id
- BG002
- value
- 6
- group Id
- BG003
- value
- 29
- title
- FRANCE
- categories
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 9
- title
- GERMANY
- categories
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 3
- title
- HUNGARY
- categories
- measurements
- group Id
- BG000
- value
- 6
- group Id
- BG001
- value
- 16
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 25
- title
- INDIA
- categories
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 8
- title
- ISRAEL
- categories
- measurements
- group Id
- BG000
- value
- 11
- group Id
- BG001
- value
- 8
- group Id
- BG002
- value
- 5
- group Id
- BG003
- value
- 24
- title
- ITALY
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Region of Enrollment
- unit Of Measure
- Participants
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice
Triangle